
David G Standaert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8580134/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	5.7	1,278
2	Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science, 2002, 296, 2238-2243.	12.6	638
3	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	3.9	608
4	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, The, 2014, 13, 141-149.	10.2	547
5	A _{2A} Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice. Journal of Neuroscience, 1999, 19, 9192-9200.	3.6	512
6	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	21.4	502
7	Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. Journal of Neuroscience, 1994, 14, 3005-3018.	3.6	489
8	Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using Wearable Sensors. IEEE Transactions on Information Technology in Biomedicine, 2009, 13, 864-873.	3.2	477
9	Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 955-960.	7.1	462
10	The pathophysiological basis of dystonias. Nature Reviews Neuroscience, 2008, 9, 222-234.	10.2	420
11	LRRK2 Inhibition Attenuates Microglial Inflammatory Responses. Journal of Neuroscience, 2012, 32, 1602-1611.	3.6	386
12	Spinal and trigeminal dorsal horn projections to the parabrachial nucleus in the rat. Journal of Comparative Neurology, 1985, 240, 153-160.	1.6	381
13	Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. Journal of Comparative Neurology, 1994, 343, 1-16.	1.6	358
14	Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane. Journal of Neuroscience, 2001, 21, 5546-5558.	3.6	349
15	MHCII Is Required for Â-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration. Journal of Neuroscience, 2013, 33, 9592-9600.	3.6	304
16	NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. Journal of Neuroscience, 1995, 15, 5297-5307.	3.6	303
17	Targeted Overexpression of Human α-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1149-1158.	1.7	295
18	CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson's Disease. Journal of NeuroImmune Pharmacology, 2012, 7, 927-938.	4.1	255

#	Article	IF	CITATIONS
19	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders, 2015, 30, 919-927.	3.9	244
20	α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nature Communications, 2020, 11, 1875.	12.8	239
21	Metabotropic glutamate receptors are differentially regulated during development. Neuroscience, 1994, 61, 481-495.	2.3	224
22	Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. , 1998, 390, 5-19.		220
23	Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Molecular Brain, 2008, 1, 17.	2.6	212
24	Effects of gender on nigral gene expression and parkinson disease. Neurobiology of Disease, 2007, 26, 606-614.	4.4	206
25	Rationale for and use of NMDA receptor antagonists in Parkinson's disease. , 2004, 102, 155-174.		204
26	Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Journal of Neuroscience, 2016, 36, 5144-5159.	3.6	204
27	Levodopa arbidopa intestinal gel in advanced Parkinson's disease: Final 12â€month, openâ€label results. Movement Disorders, 2015, 30, 500-509.	3.9	199
28	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain, 2009, 132, 2336-2349.	7.6	197
29	microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. Journal of Neuroscience, 2016, 36, 2383-2390.	3.6	195
30	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.1	194
31	Dopamine D ₁ Activation Potentiates Striatal NMDA Receptors by Tyrosine Phosphorylation-Dependent Subunit Trafficking. Journal of Neuroscience, 2006, 26, 4690-4700.	3.6	193
32	Organization of atriopeptin-like immunoreactive neurons in the central nervous system of the rat. Journal of Comparative Neurology, 1986, 253, 315-341.	1.6	187
33	Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. Journal of Comparative Neurology, 1995, 354, 241-252.	1.6	178
34	Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology, 2005, 48, 503-516.	4.1	175
35	Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease. Journal of Parkinson's Disease, 2015, 5, 1-19.	2.8	174
36	Dopamine D1-Dependent Trafficking of Striatal <i>N-</i> Methyl-d-aspartate Glutamate Receptors Requires Fyn Protein Tyrosine Kinase but Not DARPP-32. Molecular Pharmacology, 2004, 65, 121-129.	2.3	168

#	Article	IF	CITATIONS
37	Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Molecular Brain Research, 1997, 48, 259-269.	2.3	167
38	Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of Neurochemistry, 2007, 100, 070214184024010-???.	3.9	164
39	Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Experimental Neurology, 2018, 300, 179-187.	4.1	163
40	Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Molecular Brain Research, 1996, 42, 89-102.	2.3	161
41	Association of AMPA Receptors with a Subset of Glutamate Receptor-Interacting Protein <i>In Vivo</i> . Journal of Neuroscience, 1999, 19, 6528-6537.	3.6	161
42	Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. Journal of Comparative Neurology, 1999, 407, 33-46.	1.6	152
43	Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiology of Disease, 2006, 24, 318-325.	4.4	150
44	TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiology of Disease, 2003, 12, 11-24.	4.4	148
45	Targets for neuroprotection in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 676-687.	3.8	147
46	Biomarkerâ€driven phenotyping in Parkinson's disease: A translational missing link in diseaseâ€modifying clinical trials. Movement Disorders, 2017, 32, 319-324.	3.9	145
47	Gene expression profiling in the post-mortem human brain — no cause for dismay. Journal of Chemical Neuroanatomy, 2001, 22, 79-94.	2.1	144
48	Ser(P)â€1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1543-1550.	3.9	144
49	LRRK2 secretion in exosomes is regulated by 14-3-3. Human Molecular Genetics, 2013, 22, 4988-5000.	2.9	142
50	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. Npj Parkinson's Disease, 2020, 6, 11.	5.3	140
51	Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. , 1999, 415, 266-284.		138
52	Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Progress in Neurobiology, 2015, 127-128, 91-107.	5.7	136
53	Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Annals of Neurology, 1999, 46, 761-769.	5.3	135
54	Impaired Motor Learning in Mice Expressing TorsinA with the DYT1 Dystonia Mutation. Journal of Neuroscience, 2005, 25, 5351-5355.	3.6	134

#	Article	IF	CITATIONS
55	Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease. Movement Disorders, 2021, 36, 16-24.	3.9	133
56	Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Molecular Brain Research, 1999, 64, 11-23.	2.3	131
57	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. European Polymer Journal, 2017, 88, 524-552.	5.4	124
58	CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson'sÂdisease. Brain, 2021, 144, 2047-2059.	7.6	124
59	Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat. Molecular Brain Research, 1994, 21, 283-292.	2.3	122
60	Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors. Neuroscience, 2000, 97, 195-204.	2.3	121
61	Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortex. , 1998, 390, 75-90.		120
62	Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death and Disease, 2010, 1, e2-e2.	6.3	120
63	Opioid peptide immunoreactivity in spinal and trigeminal dorsal horn neurons projecting to the parabrachial nucleus in the rat. Journal of Neuroscience, 1986, 6, 1220-1226.	3.6	117
64	Inhibition of the firing of vasopressin neurons by atriopeptin. Nature, 1987, 329, 151-153.	27.8	113
65	Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Annals of Neurology, 1998, 43, 669-673.	5.3	111
66	Dopamine release is impaired in a mouse model of DYT1 dystonia. Journal of Neurochemistry, 2007, 102, 783-788.	3.9	111
67	Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. Journal of Comparative Neurology, 2014, 522, 2465-2480.	1.6	110
68	Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy and Behavior, 2018, 87, 131-136.	1.7	110
69	Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.	1.1	103
70	Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Human Molecular Genetics, 2005, 14, 179-189.	2.9	98
71	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. Npj Parkinson's Disease, 2017, 3, 10.	5.3	98
72	Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTPâ€ŧreated monkey model of parkinsonism. European Journal of Neuroscience, 2008, 27, 1647-1658.	2.6	97

#	Article	IF	CITATIONS
73	Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease. Journal of Applied Physiology, 2014, 116, 582-592.	2.5	96
74	Colocalization of atriopeptin-like immunoreactivity with choline acetyltransferase-and substance P-like immunoreactivity in the pedunculopontine and laterodorsal tegmental nuclei in the rat. Brain Research, 1986, 382, 163-168.	2.2	95
75	Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. , 2000, 419, 407-421.		95
76	Frontal Lobe Dysfunction in Progressive Supranuclear Palsy. Journal of Neurochemistry, 2001, 74, 878-881.	3.9	95
77	Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism and Related Disorders, 2013, 19, 339-345.	2.2	95
78	Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 Dystonia. Journal of Neuroscience, 2012, 32, 11991-12004.	3.6	93
79	Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiology of Disease, 2003, 14, 624-636.	4.4	92
80	Striatal histone modifications in models of levodopaâ€induced dyskinesia. Journal of Neurochemistry, 2008, 106, 486-494.	3.9	92
81	Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiology of Disease, 2010, 38, 434-445.	4.4	92
82	Update on the pathology of dystonia. Neurobiology of Disease, 2011, 42, 148-151.	4.4	92
83	Predicting the potential of wearable technology. IEEE Engineering in Medicine and Biology Magazine, 2003, 22, 23-27.	0.8	91
84	The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. Journal of Neuroinflammation, 2012, 9, 259.	7.2	89
85	How can <scp>rAAV</scp> â€î±â€synuclein and the fibril αâ€synuclein models advance our understanding of Parkinson's disease?. Journal of Neurochemistry, 2016, 139, 131-155.	3.9	84
86	Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. Journal of Neurochemistry, 2003, 85, 935-943.	3.9	81
87	Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiology of Disease, 2009, 34, 133-145.	4.4	80
88	Biochemical Fractionation of Brain Tissue for Studies of Receptor Distribution and Trafficking. Current Protocols in Neuroscience, 2008, 42, Unit 1.16.	2.6	78
89	Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Movement Disorders, 2015, 30, 1371-1381.	3.9	78
90	Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiology of Aging, 2005, 26, 1343-1355.	3.1	77

#	Article	IF	CITATIONS
91	Developmental Profile of the Aberrant Dopamine D2 Receptor Response in Striatal Cholinergic Interneurons in DYT1 Dystonia. PLoS ONE, 2011, 6, e24261.	2.5	77
92	Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Molecular Neurodegeneration, 2010, 5, 42.	10.8	74
93	NMDAR1 Glutamate Receptor Subunit Isoforms in Neostriatal, Neocortical, and Hippocampal Nitric Oxide Synthase Neurons. Journal of Neuroscience, 1998, 18, 1725-1734.	3.6	71
94	Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. Neurobiology of Disease, 2012, 47, 416-427.	4.4	71
95	VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiology of Disease, 2010, 37, 330-338.	4.4	70
96	Glutamate receptor expression in rat striatum: Effect of deafferentation. Brain Research, 1994, 647, 209-219.	2.2	69
97	Pharmacological inhibition of PARP-1 reduces α-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Biochemical and Biophysical Research Communications, 2007, 357, 596-602.	2.1	67
98	T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathologica, 2020, 139, 855-874.	7.7	66
99	Altered Dendritic Morphology of Purkinje cells in Dyt1 ΔGAG Knock-In and Purkinje Cell-Specific Dyt1 Conditional Knockout Mice. PLoS ONE, 2011, 6, e18357.	2.5	65
100	Motor Deficits and Decreased Striatal Dopamine Receptor 2 Binding Activity in the Striatum-Specific Dyt1 Conditional Knockout Mice. PLoS ONE, 2011, 6, e24539.	2.5	64
101	Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia. Experimental Neurology, 2017, 295, 162-175.	4.1	64
102	Longâ€ŧerm safety and efficacy of levodopa arbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders, 2018, 33, 928-936.	3.9	64
103	Innate and adaptive immune responses in Parkinson's disease. Progress in Brain Research, 2020, 252, 169-216.	1.4	64
104	Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiology of Disease, 2008, 29, 515-528.	4.4	62
105	A neuroprotective role for angiogenin in models of Parkinson's disease. Journal of Neurochemistry, 2011, 116, 334-341.	3.9	62
106	Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease. Journal of Neuroinflammation, 2018, 15, 244.	7.2	61
107	Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus. Journal of Comparative Neurology, 1998, 390, 63-74.	1.6	60
108	Evidence for Oxidative Stress in the Subthalamic Nucleus in Progressive Supranuclear Palsy. Journal of Neurochemistry, 2002, 73, 881-884.	3.9	60

#	Article	IF	CITATIONS
109	Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Research, 2003, 986, 12-21.	2.2	60
110	Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2892-2896.	7.1	60
111	Alternatively spliced isoforms of the NMDAR1 glutamate receptor subunit: Differential expression in the basal ganglia of the rat. Neuroscience Letters, 1993, 152, 161-164.	2.1	59
112	Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 63-68.	2.2	59
113	Huntingtin Immunoreactivity in the Rat Neostriatum: Differential Accumulation in Projection and Interneurons. Experimental Neurology, 1997, 144, 239-247.	4.1	55
114	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1058-1066.	1.7	55
115	Differential expression of kainate receptors in the basal ganglia of the developing and adult rat brain. Brain Research, 1997, 768, 215-223.	2.2	54
116	Rotigotine polyoxazoline conjugate SERâ€214 provides robust and sustained antiparkinsonian benefit. Movement Disorders, 2013, 28, 1675-1682.	3.9	54
117	Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease. PLoS ONE, 2015, 10, e0140566.	2.5	54
118	Distribution of Group III mGluRs in Rat Basal Ganglia with Subtype-Specific Antibodies. Annals of the New York Academy of Sciences, 1999, 868, 531-534.	3.8	53
119	α-Actinin-2 in rat striatum: localization and interaction with NMDA glutamate receptor subunits. Molecular Brain Research, 2000, 79, 77-87.	2.3	53
120	L-Type Ca ²⁺ Channels Mediate Adaptation of Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in the Ventral Tegmental Area after Chronic Amphetamine Treatment. Journal of Neuroscience, 2004, 24, 7464-7476.	3.6	53
121	Environmental and occupational risk factors for progressive supranuclear palsy: Case ontrol study. Movement Disorders, 2016, 31, 644-652.	3.9	53
122	Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat. Neuroscience, 1998, 86, 783-798.	2.3	51
123	Data mining techniques to detect motor fluctuations in Parkinson's disease. , 2004, 2004, 4766-9.		51
124	Immunohistochemical localization of N-methyl-d-aspartate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience, 1999, 89, 209-220.	2.3	50
125	Effect of Levodopaâ€carbidopa Intestinal Cel on Nonâ€motor Symptoms in Patients with Advanced Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 829-837.	1.5	49
126	Changes in the expression of the NR2B subunit during aging in macaque monkeys. Neurobiology of Aging, 2004, 25, 201-208.	3.1	48

#	Article	IF	CITATIONS
127	Origin of the atriopeptin-like immunoreactive innervation of the paraventricular nucleus of the hypothalamus. Journal of Neuroscience, 1988, 8, 1940-1950.	3.6	47
128	Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions. Neuroscience Letters, 1995, 202, 109-112.	2.1	47
129	Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions. Neurobiology of Disease, 2020, 134, 104708.	4.4	47
130	Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	46
131	Localization of dopaminergic markers in the human subthalamic nucleus. Journal of Comparative Neurology, 2000, 421, 247-255.	1.6	45
132	Investigating Bacterial Sources of Toxicity as an Environmental Contributor to Dopaminergic Neurodegeneration. PLoS ONE, 2009, 4, e7227.	2.5	45
133	CoQ10 in progressive supranuclear palsy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e266.	6.0	45
134	Atriopeptin: potent hormone and potential neuromediator. Trends in Neurosciences, 1985, 8, 509-511.	8.6	44
135	Dystonia and its disorders. Neurologic Clinics, 2001, 19, 681-705.	1.8	44
136	Function of dopamine transporter is compromised in DYT1 transgenic animal model <i>in vivo</i> . Journal of Neurochemistry, 2010, 113, 228-235.	3.9	43
137	Expression of N-methyl- d-aspartate glutamate receptor subunits in the prefrontal cortex of the rat. Neuroscience, 1996, 73, 417-427.	2.3	42
138	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathologica, 2006, 112, 439-449.	7.7	41
139	Expression of N-Methyl-D-Aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons. , 1998, 390, 91-101.		38
140	Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Research, 2002, 930, 170-181.	2.2	38
141	Diverse Mechanisms Lead to Common Dysfunction of Striatal Cholinergic Interneurons in Distinct Genetic Mouse Models of Dystonia. Journal of Neuroscience, 2019, 39, 7195-7205.	3.6	38
142	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. Journal of Immunology, 2019, 203, 84-92.	0.8	36
143	Parkinson's disease, primates, and gene therapy: Vive la différence?. Movement Disorders, 2011, 26, 2-3.	3.9	35
144	Alteration of Striatal Dopaminergic Neurotransmission in a Mouse Model of DYT11 Myoclonus-Dystonia. PLoS ONE, 2012, 7, e33669.	2.5	35

#	Article	IF	CITATIONS
145	N-Acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neuroscience Letters, 1997, 236, 91-94.	2.1	34
146	Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular Neurodegeneration, 2022, 17, 7.	10.8	34
147	Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia. Journal of Neuroscience, 2016, 36, 6514-6524.	3.6	33
148	Application of the â€~5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. Neurodegenerative Disease Management, 2020, 10, 309-323.	2.2	33
149	Tyrosine phosphorylation of the metabotropic glutamate receptor mGluR5 in striatal neurons. Neuropharmacology, 2002, 43, 161-173.	4.1	32
150	The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia. Journal of NeuroImmune Pharmacology, 2016, 11, 231-237.	4.1	32
151	Expression of the gene for preproatriopeptin in the central nervous system of the rat. Molecular Brain Research, 1988, 4, 7-13.	2.3	30
152	NEUROPROTECTIVE THERAPIES. Medical Clinics of North America, 1999, 83, 509-523.	2.5	30
153	Research goals in progressive supranuclear palsy. Movement Disorders, 2000, 15, 446-458.	3.9	29
154	Angiogenin in Parkinson Disease Models: Role of Akt Phosphorylation and Evaluation of AAV-Mediated Angiogenin Expression in MPTP Treated Mice. PLoS ONE, 2013, 8, e56092.	2.5	29
155	Simultaneous isotopic and nonisotopic in situ hybridization histochemistry with cRNA probes. Brain Research Protocols, 1998, 3, 22-32.	1.6	28
156	Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?. Neurobiology of Disease, 2019, 132, 104579.	4.4	27
157	Defining research priorities in dystonia. Neurology, 2020, 94, 526-537.	1.1	26
158	Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease. Npj Parkinson's Disease, 2021, 7, 36.	5.3	26
159	The TCR repertoire of α-synuclein-specific T cells in Parkinson's disease is surprisingly diverse. Scientific Reports, 2021, 11, 302.	3.3	26
160	Dopamine transmission in DYT1 dystonia. Advances in Neurology, 2004, 94, 53-60.	0.8	26
161	Cellular Distribution of NMDA Glutamate Receptor Subunit mRNAs in the Human Cerebellum. Neurobiology of Disease, 1997, 4, 35-46.	4.4	25
162	Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons. , 1999, 415, 204-217.		25

#	Article	IF	CITATIONS
163	Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse. European Journal of Neuroscience, 2006, 23, 3171-3175.	2.6	25
164	Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro. Biochemical and Biophysical Research Communications, 2007, 363, 846-851.	2.1	25
165	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. Journal of Parkinson's Disease, 2020, 10, 665-675.	2.8	25
166	<scp>Onceâ€Weekly</scp> Subcutaneous Delivery of <scp>Polymerâ€Linked</scp> Rotigotine (<scp>SER</scp> â€214) Provides Continuous Plasma Levels in Parkinson's Disease Patients. Movement Disorders, 2020, 35, 1055-1061.	3.9	24
167	Differential localization of the mRNAs for the pertussis toxin insensitive G-protein alpha sub-units Gq, G11, and Gz in the rat brain, and regulation of their expression after striatal deafferentation. Molecular Brain Research, 1998, 54, 298-310.	2.3	23
168	The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease. Brain Stimulation, 2017, 10, 651-656.	1.6	23
169	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. Parkinsonism and Related Disorders, 2021, 92, 59-66.	2.2	23
170	Applications of Laser Capture Microdissection in the Study of Neurodegenerative Disease. Archives of Neurology, 2005, 62, 203.	4.5	22
171	Racial Differences in Parkinson's Disease Medication Use in the Reasons for Geographic and Racial Differences in Stroke Cohort: A Cross-Sectional Study. Neuroepidemiology, 2009, 33, 329-334.	2.3	22
172	Bridging the Gaps: More Inclusive Research Needed to Fully Understand Parkinson's Disease. Movement Disorders, 2020, 35, 231-234.	3.9	22
173	<scp>DUOGLOBE</scp> : One‥ear Outcomes in a <scp>Realâ€World</scp> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1061-1074.	1.5	22
174	Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatmentâ€Resistant Epilepsy. Clinical Pharmacology and Therapeutics, 2021, 110, 1368-1380.	4.7	22
175	Using wearable sensors to predict the severity of symptoms and motor complications in late stage Parkinson's Disease. , 2008, 2008, 3686-9.		21
176	Dysregulation of BET proteins in levodopa-induced dyskinesia. Neurobiology of Disease, 2017, 102, 125-132.	4.4	21
177	DNA Fragmentation and Immediate Early Gene Expression in Rat Striatum Following Quinolinic Acid Administration. Experimental Neurology, 1995, 133, 207-214.	4.1	20
178	NMDA-R1 antisense oligodeoxynucleotides modify formalin-induced nociception and spinal c-Fos expression in rat spinal cord. Pharmacology Biochemistry and Behavior, 2004, 79, 183-188.	2.9	20
179	Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures. Npj Parkinson's Disease, 2022, 8, 30.	5.3	20
180	Effects of Subthalamic Nucleus Deep Brain Stimulation on Objective Sleep Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 183-190.	1.5	19

#	Article	IF	CITATIONS
181	Implementing Levodopaâ€Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. Movement Disorders Clinical Practice, 2018, 5, 383-393.	1.5	19
182	Identification of Nitric Oxide Synthase Neurons for Laser Capture Microdissection and mRNA Quantification. BioTechniques, 2002, 33, 1274-1283.	1.8	18
183	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. Parkinsonism and Related Disorders, 2019, 69, 34-39.	2.2	18
184	Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia. Neurobiology of Disease, 2022, 166, 105650.	4.4	18
185	Transduction of Brain Dopamine Neurons by Adenoviral Vectors Is Modulated by CAR Expression: Rationale for Tropism Modified Vectors in PD Gene Therapy. PLoS ONE, 2010, 5, e12672.	2.5	17
186	Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Molecular Brain Research, 2002, 101, 132-135.	2.3	16
187	Understanding falls in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2017, 35, 75-81.	2.2	15
188	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209.	2.2	15
189	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. Journal of Parkinson's Disease, 2020, 10, 677-691.	2.8	15
190	Exploring human-genome gut-microbiome interaction in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 74.	5.3	15
191	Design of clinical trials of gene therapy in Parkinson disease. Experimental Neurology, 2008, 209, 41-47.	4.1	14
192	A Full-Brain, Bootstrapped Analysis of Diffusion Tensor Imaging Robustly Differentiates Parkinson Disease from Healthy Controls. Neuroinformatics, 2015, 13, 7-18.	2.8	14
193	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Movement Disorders, 2018, 33, 468-472.	3.9	14
194	Fiber-Modified Adenovirus for Central Nervous System Parkinson's Disease Gene Therapy. Viruses, 2014, 6, 3293-3310.	3.3	13
195	Alpha-synuclein–mediated DNA damage, STING activation, and neuroinflammation in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2204058119.	7.1	13
196	Hypertension and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 166-170.	2.2	12
197	Levodopa-Induced Dyskinesia Is Associated with Increased Thyrotropin Releasing Hormone in the Dorsal Striatum of Hemi-Parkinsonian Rats. PLoS ONE, 2010, 5, e13861.	2.5	12
198	RORγt-Expressing Pathogenic CD4+ T Cells Cause Brain Inflammation during Chronic Colitis. Journal of Immunology, 2022, 208, 2054-2066.	0.8	11

#	Article	IF	CITATIONS
199	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease, 2021, 7, 16.	5.3	10
200	The emerging postural instability phenotype in idiopathic Parkinson disease. Npj Parkinson's Disease, 2022, 8, 28.	5.3	10
201	Processing Wearable Sensor Data to Optimize Deep-Brain Stimulation. IEEE Pervasive Computing, 2008, 7, 56-61.	1.3	9
202	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism and Related Disorders, 2020, 78, 56-60.	2.2	9
203	Templated α-synuclein inclusion formation is independent of endogenous tau. ENeuro, 2021, 8, ENEURO.0458-20.2021.	1.9	9
204	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. Journal of Parkinson's Disease, 2022, 12, 917-926.	2.8	9
205	Advanced Analysis of Wearable Sensor Data to Adjust Medication Intake in Patients with Parkinson?s Disease. , 0, , .		8
206	Metabolomics and the search for biomarkers in Parkinson's disease. Movement Disorders, 2013, 28, 1620-1621.	3.9	8
207	Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia. Frontiers in Systems Neuroscience, 2017, 11, 43.	2.5	8
208	Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics. Npj Parkinson's Disease, 2018, 4, 4.	5.3	8
209	Inherited movement disorders. Neurologic Clinics, 2002, 20, 759-778.	1.8	7
210	Monocytes and Parkinson's Disease: Invaders From Outside?. Movement Disorders, 2014, 29, 1242-1242.	3.9	7
211	Child Neurology: Spastic paraparesis and dystonia with a novel ADCY5 mutation. Neurology, 2019, 93, 510-514.	1.1	7
212	Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. Journal of Comparative Neurology, 1998, 390, 5-19.	1.6	7
213	Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method. Diagnostics, 2022, 12, 1161.	2.6	7
214	Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Movement Disorders Clinical Practice, 2016, 3, 65-67.	1.5	6
215	Genetic influences on cognition in progressive supranuclear palsy. Movement Disorders, 2017, 32, 1764-1771.	3.9	6
216	Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 89-92.	2.2	6

#	Article	IF	CITATIONS
217	Target validation: the Parkinson disease perspective. DMM Disease Models and Mechanisms, 2010, 3, 259-262.	2.4	5
218	Reply to letter: Suicide in <scp>P</scp> arkinson's disease patients treated with levodopa arbidopa Intestinal Gel. Movement Disorders, 2015, 30, 1435-1436.	3.9	5
219	Using Wearable Sensors to Enhance DBS Parameter Adjustment for Parkinson's Disease Patients Through Measures of Motor Response. , 2006, , .		4
220	Evaluation of TorsinA as a Target for Parkinson Disease Therapy in Mouse Models. PLoS ONE, 2012, 7, e50063.	2.5	4
221	Reaping what you sow: Crossâ€seeding between aggregationâ€prone proteins in neurodegeneration. Movement Disorders, 2014, 29, 306-306.	3.9	4
222	<scp>B</scp> iomarkers in <scp>P</scp> arkinson's disease: <scp>F</scp> rom pathophysiology to early diagnosis. Movement Disorders, 2016, 31, 769-770.	3.9	4
223	The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy. Journal of Parkinson's Disease, 2017, 7, 377-383.	2.8	4
224	SNPing <i>SCNA</i> regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease. Movement Disorders, 2016, 31, 1479-1479.	3.9	3
225	What would Dr. James Parkinson think today? Mutations in betaâ€glucocerebrosidase and risk of Parkinson's disease. Movement Disorders, 2017, 32, 1341-1342.	3.9	3
226	Removing the blinkers: moving beyond striatal dopamine in Parkinson's disease. Journal of Neurochemistry, 2013, 125, 639-641.	3.9	2
227	Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. Journal of Comparative Neurology, 2014, 522, Spc1-Spc1.	1.6	2
228	Progressive Supranuclear Palsy and Statin Use. Movement Disorders, 2020, 35, 1253-1257.	3.9	2
229	Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis. Parkinsonism and Related Disorders, 2021, 86, 52-57.	2.2	2
230	Introduction: Adenosine A _{2A} receptor modulation of motor systems for symptomatic therapy in Parkinson's disease. Neurology, 2003, 61, S30-1.	1.1	2
231	Localization of Adenosine Receptors in Brain and Periphery. , 2000, , 17-30.		2
232	Immunohistochemical localization of metabotropic glutamate receptors (mGluRs) in the rat basal ganglia. Neuropharmacology, 1996, 35, A30.	4.1	1
233	Invisible Killers. Movement Disorders, 2016, 31, 44-44.	3.9	1
234	Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats. Movement Disorders Clinical Practice, 2019, 6, 336-337.	1.5	1

#	Article	IF	CITATIONS
235	Gene-Environment Interactions in Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 664796.	2.4	1
236	Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. Journal of Comparative Neurology, 1999, 415, 266-284.	1.6	1
237	DYT1 Transgenic Mouse. , 2005, , 287-292.		1
238	<scp>John Q. Trojanowski, MD, PhD</scp> (1946–2022). Movement Disorders, 2022, 37, 1123-1124.	3.9	1
239	Magnetic Resonance Angiography in the Evaluation of Dural Carotidâ€Cavernous Fistulas. Journal of Neuroimaging, 1992, 2, 208-211.	2.0	Ο
240	Metabotropic glutamate receptors modulate striatal quinolinic acid toxicity. Neuropharmacology, 1996, 35, A22.	4.1	0
241	Sex Differences in Parkinson's Disease. , 2007, , 455-464.		0
242	O.045 Mechanisms of dystonia. Parkinsonism and Related Disorders, 2009, 15, S12.	2.2	0
243	Basal Ganglia Disorders. , 2013, , 1-39.		Ο
244	Scientific perspectives. Movement Disorders, 2014, 29, 1230-1230.	3.9	0
245	Glucocerebrosidase, <scp>P</scp> arkinson disease, and the "senses and intellectâ€. Annals of Neurology, 2016, 80, 660-661.	5.3	Ο
246	Cholinergic regulation of striatal dopamine release: New light in dark basements. Movement Disorders, 2016, 31, 1796-1796.	3.9	0
247	Brain Alchemy: Transforming Astrocytes into Neurons for Neurodegenerative Disease. Movement Disorders Clinical Practice, 2020, 7, 902-903.	1.5	Ο
248	Neuroprotective Strategies for Parkinsons Disease. Current Neuropharmacology, 2004, 2, 309-322.	2.9	0
249	Neurogenetics Of Dystonia And Paroxysmal Dyskinesias. Neurological Disease and Therapy, 2005, , 396-419.	0.0	0
250	Torsion Dystonia. , 2009, , 1029-1034.		0
251	Basal Ganglia Disorders. , 2014, , .		0
252	Role of Atriopeptin in Central Cardiovascular Control. , 1988, , 151-162.		0

#	Article	IF	CITATIONS
253	STANDAERT, David G.: Alabama/USA. , 2019, , 139-142.		0
254	Wearable technology's applications in Parkinson's disease. IEEE Engineering in Medicine and Biology Magazine, 2003, 22, 25-6.	0.8	0